A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

Norman David Eansor net worth and biography

Norman Eansor Biography and Net Worth

Insider of Bio-Techne

Dave Eansor was appointed President of the Protein Sciences Segment in July 2018. Prior to that, Mr. Eansor was the Senior Vice President of the Biotech Division. Mr. Eansor joined Bio-Techne through the acquisition of Novus Biologicals in July 2014. Prior to joining Novus Biologicals in 2013, Mr. Eansor was the President of the ~$1 Billion Bioscience Division of Thermo Fisher Scientific. Mr. Eansor was promoted to Division President in early 2010 after 5 years as President of Thermo Fisher's Life Science Research business. Prior to joining Thermo Fisher Scientific, Mr. Eansor spent 5 years as President of Cambrex Bioproducts. Prior to joining Cambrex, Mr. Eansor spent 19 years with R. P. Scherer Corporation, a contract pharmaceutical drug delivery manufacturer which was acquired by Cardinal Health and later Catalent. There he held various senior management positions, the last of which was Vice President of Pharmaceutical Operations.

Mr. Eansor has a Bachelor of Science in Chemistry from University of Western Ontario, a Bachelor of Commerce in General Business and Economics, and a Master of Business Administration from the University of Windsor, Ontario, Canada.

What is Norman David Eansor's net worth?: The estimated net worth of Norman David Eansor is at least $1.04 million as of March 16th, 2023. Mr. Eansor owns 16,713 shares of Bio-Techne stock worth more than $1,037,710 as of April 18th. This net worth approximation does not reflect any other assets that Mr. Eansor may own. Learn More about Norman David Eansor's net worth.
How do I contact Norman David Eansor?: The corporate mailing address for Mr. Eansor and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at [email protected]. Learn More on Norman David Eansor's contact information.
Has Norman David Eansor been buying or selling shares of Bio-Techne?: Norman David Eansor has not been actively trading shares of Bio-Techne in the last ninety days. Most recently, Norman David Eansor sold 27,159 shares of the business's stock in a transaction on Friday, November 12th. The shares were sold at an average price of $504.00, for a transaction totalling $13,688,136.00. Learn More on Norman David Eansor's trading history.
Who are Bio-Techne's active insiders?: Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), John Higgins (Director), James Hippel (CFO), Kim Kelderman (Insider), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.
Are insiders buying or selling shares of Bio-Techne?: In the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 99,339 shares worth more than $8,587,372.48. The most recent insider tranaction occured on March, 7th when Director Roeland Nusse sold 10,400 shares worth more than $800,592.00. Insiders at Bio-Techne own 4.5% of the company. Learn More about insider trades at Bio-Techne.
Information on this page was last updated on 3/7/2024.

Norman David Eansor Insider Trading History at Bio-Techne

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/12/2021	Sell	27,159	$504.00	$13,688,136.00
8/31/2021	Sell	1,538	$503.07	$773,721.66
5/28/2020	Sell	3,448	$260.19	$897,135.12	3,448
5/21/2020	Sell	11,037	$267.49	$2,952,287.13	11,037
6/12/2019	Sell	3,117	$215.00	$670,155.00

Norman David Eansor Buying and Selling Activity at Bio-Techne

Bio-Techne Company Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Today's Range

Now: $62.09

$61.16

$62.43

50 Day Range

MA: $70.73

$62.73

$77.09

2 Week Range

Now: $62.09

$51.79

$89.91

Volume

387,665 shs

Average Volume

1,060,810 shs

Market Capitalization

$9.76 billion

P/E Ratio

44.99

Dividend Yield

0.50%

Beta

1.22